Table 2 Clinical characteristics and resultsa
Characteristics | n = 29 |
|---|---|
Time from symptom onset to ICU admission; days | 10 (8.5–11) |
Lymphocyte count on admission; /mm3 | 911 (708–1185) |
C-reactive protein level on admission; mg/L | 80 (62.0–170.5) |
Platelet count < 100 000/mm3 during ICU stay | 3 (10.3%) |
Respiratory support | |
None | 1 (3.4%) |
NC or non-rebreather mask with reservoir bag | 28 (96.6%) |
HFNC and/or NIV | 18 (62.1%) |
Subsequent intubation | 12 (41.4%) |
No subsequent intubation | 6 (20.7%) |
IMV | 16 (55.2%) |
Time from symptom onset to intubation; days | 12 (10.2–14.0) |
IMV time; days | 16.5 (9.2–22.0) |
PEEP associated with best compliance (cmH2O) | 11 (10–12) |
PP in intubated patients | 11 (37.8%) |
Number of sessions per patient | 2 (1–8) |
PaO2/FiO2 before PP | 105.6 ± 22.2 |
PaO2/FiO2 during first PP session | 262.9 ± 77.7 |
ECMO* | 0 (0.0%) |
Tracheostomy | 7 (24.1%) |
Time between TI† and TT‡; days | 16.7 ± 4.9 |
Continuous sedation | 16 (55.2%) |
NMBA | 15 (51.7%) |
Neuromuscular blocking time; days | 8.1 ± 4.6 |
Amines | |
Noradrenaline | 12 (41.4%) |
Dobutamine/epinephrine/dopamine/phenylephrine | 0 (0.0%) |
Transfusion; number of patients | 4 (13.8%) |
Corticosteroids | 29 (100%) |
Corticosteroid time; days | 12 (10–18) |
Antibiotics | 27 (93.1%) |
Anticoagulants | |
Prophylactic enoxaparin | 27 (93.1%) |
Therapeutic enoxaparin | 2 (6.9%) |
Remdesivir, tocilizumab | 0 (0.0%) |
Length of ICU stay | 14 (4.5–23.0) |
Length of hospital stay | 20 (11.0–31.5) |
Death | |
Maternal | 0 (0.0%) |
Fetal (stillborn) | 2 (6.9%) |
Neonatal | 0 (0.0%) |